|Videos|December 23, 2020
New Mechanism for Treatment of Schizophrenia
Author(s)Stephen Brannan, MD
Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.
Advertisement
Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.
To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see
Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Mental Health Grants Cut Then Restored in 24 Hours: Leading Organizations React to Environment of Uncertainty
2
Muscarinic Cholinergic Circuitry in Schizophrenia: Our Evolving Understanding
3
sNDA Submission: Igalmi for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia in Outpatient Setting
4
New ADHD Medications Discussed at APSARD 2026
5